Results for tag: "Inclisiran"

Inclisiran is a cardiovascular drug that is used to reduce the risk of cardiovascular events in adults with established cardiovascular disease. It is a small interfering RNA (siRNA) drug that works by blocking the production of a protein called PCSK9, which is involved in the regulation of cholesterol levels. Inclisiran is administered as a subcutaneous injection, and is typically given twice a year. The Inclisiran market is composed of pharmaceutical companies that develop, manufacture, and market the drug. Companies in this market include Novartis, The Medicines Company, and Alnylam Pharmaceuticals. These companies are focused on providing innovative treatments for cardiovascular diseases, and are actively researching and developing new therapies to improve patient outcomes. Show Less Read more